Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000216910
Ethics application status
Approved
Date submitted
22/06/2010
Date registered
28/02/2011
Date last updated
7/07/2022
Date data sharing statement initially provided
7/07/2022
Date results provided
7/07/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
Chronotherapy (timed ingestion of medicine) for high blood pressure in patients with obstructive sleep apnoea (OSA)
Scientific title
A double-blinded, randomised, placebo-controlled, crossover study to assess the efficacy of morning or bed-time Perindopril (10mg) to treat hypertension in adult patients with Obstructive Sleep Apnoea
Secondary ID [1] 252070 0
n/a
Universal Trial Number (UTN)
Trial acronym
CH-OSA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertension 257610 0
Obstructive Sleep Apnoea 257663 0
Condition category
Condition code
Cardiovascular 257785 257785 0 0
Hypertension
Respiratory 257786 257786 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Following screening, patients on Angiotensin Converting Enzyme Inhibitors (ACE-i) or Angiotensin Receptor Blockers (ARBs) will undertake a washout period of 3 weeks.

All patients will then undergo a run-in period with perindopril 10mg (morning dose) to ensure medication tolerability. The run in period will be 1 week for those previously taking ACE-i, 2 weeks for those previously on ARBs, and 4 weeks for all patients.

Patients will then be randomised to one of two anti-hypertensive treatment orders for 6 weeks and then cross over to the alternative order. The two treatment orders are.

Treatment Order 1: Perindopril 10 mg morning dose and placebo bedtime dose
Treatment Order 2: Placebo morning dose and Perindopril 10mg bedtime dose

There is no washout period between the two treatment orders.

Following completion of both treatment orders, patients will continue with their last allocated anti-hypertensive treatment order (1 or 2) and also receive Continous Positive Airway Pressure (CPAP) treatment in an open label design for 8 weeks. CPAP will be delivered via a nasal mask and the pressure will be individually titrated during an in-laboratory pressure determination study prior to commencement of 8 weeks CPAP therapy. The pressure will be titrated to a level that fully prevents apnoeas and hypopneas and normalizes breathing during sleep. During the 8 weeks of CPAP treatment, patients will be encouraged to use the device every night for the entire sleep period.
Intervention code [1] 256695 0
Treatment: Drugs
Intervention code [2] 256696 0
Treatment: Devices
Comparator / control treatment
The placebo pill will be produced by the same manufacturer (Servier) as the active drug. The placebo tablet will be identical to the active tablet except that the active ingredient will not be added
Control group
Placebo

Outcomes
Primary outcome [1] 258656 0
Nigh time systolic blood pressure (determined from 24-hour ambulatory blood pressure monitoring (ABPM) in Obstructive Sleep Apnoea patients.
Timepoint [1] 258656 0
Baseline (week 0), visit 5 (End of Treatment Arm 1,week 10) visit 6 (End of Treatment Arm 2,week 16) Visit 7 (End of CPAP Arm week 24)
Secondary outcome [1] 264632 0
Examine the changes in other Blood Pressure indices (24 hour, daytime, night time and office Blood Pressure) and, arterial stiffness and central Blood Pressure (using Pulse Wave Analysis).
Timepoint [1] 264632 0
Baseline (week 0), visit 5 (End of Treatment Arm 1, week 10) visit 6 (End of Treatment Arm 2, week 16) Visit 7 (End of CPAP Arm, week 24)
Secondary outcome [2] 302304 0
Explanatory/Efficacy outcome: Pharmacokinetics. The phramocokinetics of the study drug perindopril will be investigated over a 24 hour period in a small subgroup of patients. This will help explain any differences in antihypertensive effects observed between a morning and evening dose before and after the addition of CPAP treatment for sleep apnoea.
Timepoint [2] 302304 0
Pharmacokinetics will be examined across 24 hours at the end of the drug treatment arm (6 weeks morning versus 6 weeks evening dose) and then after 2 months treatment with CPAP.

Eligibility
Key inclusion criteria
The maximum age is 65 years as stated below. This amendment was approved by the ethics committee on 01/06/2011.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Pregnancy.
Abnormal renal function or chronic kidney disease indicated by any of
1. raised creatinine (>110umol/L)
2. raised potassium (>5.0 mmol/L)
3. low eGFR (<60ml/min/1.73m2)
Severe hypertension (SBP>=180 and/or DBP>=110)
Drug resistant hypertension defined as taking more than 3 classes of BP medication
Normal Office BP (< 140/90 mmHg) whilst taking anti-hypertensive medication that does not include an ACE or ARB.
ACE Inhibitor intolerance (based on the opinion of participants and study physicians) indicated by the development of new cough or symptoms of hypotension (dizziness).
Unwilling to undergo washout of ACE or ARB medication.
Shift workers who rotate to night shift.
Poorly controlled diabetes defined as Glycosolated Haemoglobin (HbA1c) >=8.
Unstable Angina / Heart Failure (NYHA Class III and IV)/ Stroke.
Recent (< 6 months) AMI or Revascularisation Procedure.
Significant Arrhythmia or Atrial Fibrillation.
Cognitive impairment / Psychiatric disorder / Physically unable to participate.
Recent OSA treatment with Mandibular Advancement Splint or CPAP exposure (within 3 months of screening) or prior refusal of CPAP treatment.
Severe OSA (minimum oxygen saturation < 65% or RDI > 80) or excessively sleepy patients at increased risk for driving-related accidents requiring immediate treatment.
More than 20% of AHI with central apnoeas.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
After informed and written consent, patients will be sequentially enrolled according to a randomised list generated via a computer program by a third party who had no involvement in the trial. The outcome of which will result in sequentially numbered drug packs being distributed to sequentially enrolled subjects. Each subject will be randomised to one of the two treatment orders:
1. Perindopril morning and Placebo evening or
2. Placebo morning and Perindopril evening and then crossing over to the alternative order.
This final order will continue with an additional arm of CPAP treatment in OSA patients.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The treatment sequence was according to a randomised, block design. It was computer generated using a SAS program utilising the RANUNI function and a random seed.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/03/2011
Actual
17/03/2011
Date of last participant enrolment
Anticipated
28/11/2014
Actual
28/01/2015
Date of last data collection
Anticipated
Actual
28/07/2015
Sample size
Target
82
Accrual to date
Final
85
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 895 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 4601 0
Royal Prince Alfred Hospital - Camperdown

Funding & Sponsors
Funding source category [1] 257164 0
Government body
Name [1] 257164 0
National Health and Medical Research Council NHMRC
Country [1] 257164 0
Australia
Primary sponsor type
Individual
Name
Dr C Phillips - Principle Investigator
Address
Dept Respiratory & Sleep Medicine Level 8, Acute Services Building, Royal North Shore Hospital St Leonards NSW 2065
Country
Australia
Secondary sponsor category [1] 256419 0
None
Name [1] 256419 0
Address [1] 256419 0
Country [1] 256419 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 259205 0
Hawkesbury Ethics Review Committee of Northern Sydney Central Coast Health
Ethics committee address [1] 259205 0
Ethics committee country [1] 259205 0
Australia
Date submitted for ethics approval [1] 259205 0
16/03/2010
Approval date [1] 259205 0
30/06/2010
Ethics approval number [1] 259205 0
HREC/10/HARBR/51

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 31315 0
Dr Craig Phillips
Address 31315 0
Dept Respiratory & Sleep Medicine, Level 8, Acute Services Building, Royal North Shore Hospital, St Leonards NSW 2065, Australia
Country 31315 0
Australia
Phone 31315 0
+61 2 94632936
Fax 31315 0
Email 31315 0
craig.phillips@sydney.edu.au
Contact person for public queries
Name 14562 0
Yasmina Djavadkhani
Address 14562 0
The Woolcock institute of medical research
431 Glebe Point Rd Glebe NSW 2037
Country 14562 0
Australia
Phone 14562 0
+61291140414
Fax 14562 0
+61 2 91140011
Email 14562 0
chosa@woolcock.org.au
Contact person for scientific queries
Name 5490 0
Craig Phillips
Address 5490 0
The Woolcock institute of medical research
431 Glebe Point Rd Glebe NSW 2037
Country 5490 0
Australia
Phone 5490 0
+61 2 91140301
Fax 5490 0
+61 2 91140011
Email 5490 0
craig.phillips@sydney.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Individual participant underlying published results only.
When will data be available (start and end dates)?
Data will be made available upon request, after publication, with no end date determined.
Available to whom?
Data will be made available upon request, after publication and will be determined upon negotiation with researchers who provided a methodologically sound proposal.
Available for what types of analyses?
Any purpose.
How or where can data be obtained?
Secure data transfer and signed data access agreement. Contact: chosa@woolcock.org.au


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseChronotherapy for hypertension in obstructive sleep apnoea (CHOSA): A randomised, double-blind, placebo-controlled crossover trial.2017https://dx.doi.org/10.1136/thoraxjnl-2016-209504
N.B. These documents automatically identified may not have been verified by the study sponsor.